|
Repurposing a Potent MDM2 Inhibitor for Leukemia Treatment
Application
VERU-111, also known as sabizabulin, is a potent microtubule inhibitor and, notably, an MDM2 inhibitor. This repurposed compound demonstrates remarkable efficacy in the treatment of Acute Myeloid Leukemia (AML).
Key Benefits
Unique dual-action functionality as a microtubule and MDM2 inhibitor.
Successful inhibition of MDM2, an oncogene...
Published: 4/23/2024
Contributor(s): Deborah DeRyckere, Muxiang Zhou, Lu Bing Gu, Douglas Graham, Tao Liu
|
|
Repurposing an FDA-Approved Drug for Treating Age-Associated Lung Fibrosis
Application
New use of an FDA-approved therapeutic, diroximel fumarate (Vumerity), for treating Idiopathic Pulmonary Fibrosis.
Key Benefits
Novel use of an FDA-approved drug, diroximel fumarate - DRF (Vumerity), for treating age-dependent lung fibrosis.
Lung-targeted inhaled delivery of DRF is effective for boosting lung antioxidant responses...
Published: 4/23/2024
Contributor(s): Louise Hecker, Kosuke Kato
|
|
ONC201 for the Treatment of Vascular Aneurysms
Application
A repurposed therapeutic for the preventative and treatment of aneurysms.
Key Benefits
A repurposed cancer drug that targets cells known to be damaged during the progression of an aneurysm.
The drug has been tested within an animal model of aortic aneurysms, where it prevented the severe complications of the disease and protected the...
Published: 3/1/2024
Contributor(s): Alejandra Maria San Martin
|
|
Therapeutic to Treat Age-Dependent Idiopathic Pulmonary Fibrosis
Application
Therapeutic for treating age-associated lung fibrosis.
Key Benefits
Tecfidera (dimethyl fumarate - DMF) is an FDA approved therapy to treat multiple sclerosis via oral administration.
A novel formulation for inhaled delivery demonstrated efficacy for a new indication: Idiopathic Pulmonary Fibrosis (IPF), where it promotes the reversal...
Published: 4/23/2024
Contributor(s): Louise Hecker, Kosuke Kato, Priyadarshini Muralidharan, Heidi Mansour
|
|
A Predictive Marker and Treatment to Sensitize Multiple Myeloma Patients to Venetoclax (ABT-199)
Application
A marker that predicts Venetoclax (ABT-199) sensitivity that can also be targeted with a drug to help multiple myeloma patients.
Key Benefits
Marker that predicts if venetoclax will be an effective treatment in multiple myeloma patients.
A drug that targets venetoclax resistant multiple myeloma cells to improve treatment in patients.
Market...
Published: 4/23/2024
Contributor(s): Malathy (mala) Shanmugam, Richa Bajpai
|
|
Repurposed Treatment for Cocaine Use Disorder
Application
Repurposed drug for transcriptomic-driven treatment of cocaine use disorder.
Key Benefits
FDA-approved drug.
Outperformed current targets undergoing clinical trials for CUD at the mRNA level.
Market Summary
Cocaine abuse is associated with substantial morbidity and mortality, and there are no approved medications for the treatment...
Published: 3/1/2024
Contributor(s): Rohan Palmer, Spencer Huggett
|
|
Drug Combination to Treat Lung Cancer Metastasis
Application
Combination product co-targeting PDH and GLUT1 to inhibit lung cancer metastasis.
Key Benefits
Combination of drugs exhibits greater synergism in cancer cell lines (H1299, 4T1, H1792).
Has potential to prevent metastasis in a variety of cancers.
Decreases both cell viability and invasive area.
Repurposed drugs.
Market Summary
Metastatic...
Published: 4/23/2024
Contributor(s): Malathy (mala) Shanmugam, Adam Marcus
|
|
HDAC Inhibitors for Managing Vascular Conditions and Diabetic Peripheral Neuropathies
Application
Treatment of diabetic neuropathy using epigenetic modulators, histone deacetylase inhibitors (HDACis), to ameliorate or prevent vascular conditions and neuropathic pains by nerve damages.
Key Benefits
Reverses or protects against diabetes-induced nerve damages by direct injection of HDACi.
Relatively low regulatory risk because many...
Published: 4/23/2024
Contributor(s): Young-Sup Yoon, Ji Woong (Jay) Han, Hyunsuk Shim
|
|
Therapeutic Compounds Inhibiting DUSP5 and DUSP6 for Cardiomyocyte Proliferation and Cardiac Regeneration
Application
Therapeutics using siRNAs and small molecules to treat congenital heart defect and myocardial injuries.
Key Benefits
Reactivates cardiomyocyte (CM) cell replication, allowing regeneration of heart muscle after cardiac injuries.
Therapeutic compounds may be administered for transient regeneration/repair of heart muscle after cardiac...
Published: 7/28/2023
Contributor(s): Ahsan Husain, Nawazish Naqvi
|
|
Small Molecules to Promote Bone Growth
Application
Small molecule sclerostin-inhibitors to enhance the canonical Wnt pathways and promote BMP-induced osteoblast differentiation.
Key Benefits
Repurposing opportunities of FDA approved drugs.
Lower cost compared to currently available monoclonal antibody or recombinant protein therapies.
Stable compounds with established safety profiles...
Published: 4/23/2024
Contributor(s): Scott Boden, Steven Presciutti, Sreedhara Sangadala
|